Also, agents targeting the IGF-1R/AKT and TGFBRI/SMAD2/3 signaling pathways have demonstrated anti-tumor activity in preclinical studies and are being evaluated in clinical trials for their efficacy and safety in Wilms tumor patients [63]. This evidence concerns the gene IGF1R and Wilms tumor.